Clinical Trials Browser

Interventional × Biliary Tract Neoplasms × Trastuzumab × Clear all

Biliary Tract Neoplasms

NCT06178445 2026-03-27

TRAP-BTC

Phase 2 Active not recruiting

24 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT07062263 2025-07-14

TAB-2

Phase 3 Recruiting

220 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03613168 2021-01-05

BILHER

Phase 2 Completed

4 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03185988 2019-07-19

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Phase 2 Unknown

100 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Colorectal Neoplasms

Clinical Trials

SAFIR-ABC10

TRAP-BTC

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

TAB-2

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

BILHER

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System